Trademark Filing
Daiichi Sankyo Company, Limited
| Serial Number | 79337738 |
| Mark Drawing Code | 2000: Illustration: Drawing or design without any word(s)/letter(s)/ number(s) |
Timeline
| 2022-01-19 | Application Filed |
| 2022-04-07 | Location: INITIAL REVIEW/SERIALIZATION BRANCH(MAILROOM) |
| 2022-04-07 | Status: Live/Pending |
| 2022-04-21 | Transaction Date |
Trademark Applicants & Owners
| Owner: |  DAIICHI SANKYO COMPANY, LIMITED |
| Address | 3-5-1, Nihonbashi Honcho, Chuo-ku Tokyo 103-8426 JP |
| Legal Entity Type | Corporation |
| Legal Entity State | JP |
Documents
Click the blue "Refresh" button to load certificates, specimines, application, and other documents.
Design Search Codes
| 260101 | Circles as carriers or as single line borders |
| 260104 | Circles with two breaks or divided in the middle |
| 260106 | Circles, semi; Semi |
| 260128 | Circles with irregular circumferences; Miscellaneous circular designs with an irregular circumference |
| 260515 | Four or more triangles; Triangles |
| 260516 | Triangles touching or intersecting |
| 260521 | Triangles that are completely or partially shaded |
| 260525 | Triangles with one or more curved sides |
| 261709 | Bands, curved; Bars, curved; Curved line(s), band(s) or bar(s); Lines, curved |
Attorney of Record
Good, Services, and Codes
| International Codes: | 5 |
| U.S. Codes: | 005,006,018,044,046,051,052 |
| Type Code | Type |
|---|---|
| GS0051 | Pharmaceutical preparations for the treatment and prevention of cancer, oncological diseases, leukemia, musculoskeletal disorders, muscular dystrophy, pseudoxanthoma, dermatological disorders, allergy, cardiovascular diseases, kidney diseases, fibrodysplasia ossificans progressiva; vaccines for human use |
Trademark Filing History
| Description | Date | Event Coding |
|---|---|---|
| SN ASSIGNED FOR SECT 66A APPL FROM IB | 2022-04-07 | 1 REPR M: |
| LIMITATION FROM ORIGINAL APPLICATION ENTERED | 2022-04-15 | 2 LIMI I:Incoming Correspondence |
| NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM | 2022-04-21 | 3 NWOS I:Incoming Correspondence |
| APPLICATION FILING RECEIPT MAILED | 2022-04-26 | 4 MAFR O:Outgoing Correspondence |
| NEW REPRESENTATIVE AT IB RECEIVED | 2022-06-04 | 5 NREP P: |
| NEW REPRESENTATIVE AT IB RECEIVED | 2022-07-03 | 6 NREP P: |
| ASSIGNED TO EXAMINER | 2022-10-28 | 7 DOCK D:Assigned to Examiner |
| NON-FINAL ACTION WRITTEN | 2022-11-01 | 8 CNRT R:Renewal |
| NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | 2022-11-02 | 9 RFCR E:E-Mail |
| REFUSAL PROCESSED BY MPU | 2023-01-13 | 10 RFRR P: |
| NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | 2023-01-13 | 11 RFCS P: |
| REFUSAL PROCESSED BY IB | 2023-02-07 | 12 RFNT P: |
| TEAS RESPONSE TO OFFICE ACTION RECEIVED | 2023-07-12 | 13 TROA I:Incoming Correspondence |
| CORRESPONDENCE RECEIVED IN LAW OFFICE | 2023-07-12 | 14 CRFA I:Incoming Correspondence |
| TEAS/EMAIL CORRESPONDENCE ENTERED | 2023-07-12 | 15 TEME I:Incoming Correspondence |
| NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | 2023-09-13 | 16 OPNR P: |
| NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | 2023-09-13 | 17 OPNS P: |
| NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | 2023-10-03 | 18 OPNX P: |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.
| 